Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shahbaz Khan

Psychiatry Kansas City, MO Medical Doctor

NPI 1962591313 CMS profile 362168

4240 Blue Ridge Blvd, Suite 301, Kansas City, MO 64133

Open in the dashboard

General payments

$1,840

25 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shahbaz Khan of Kansas City, MO is reported in the CMS Open Payments database as having received $1,840 across 25 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,484 3
2023 General $40 2
2020 General $60 4
2019 General $256 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shahbaz Khan
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Shahbaz Khan were reported at $1,484. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Shahbaz Khan Psychiatry median Middle half National median
2019 $256 $184 $59–$605 $163
2020 $60 $119 $36–$372 $114
2021 $0 $143 $43–$576 $132
2022 $0 $153 $50–$590 $149
2023 $40 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $1,484 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Neuronetics, Inc. $1,484 3 payments
  2. Janssen Pharmaceuticals, Inc $133 6 payments
  3. Otsuka America Pharmaceutical, Inc. $71 5 payments
  4. Sunovion Pharmaceuticals Inc. $49 3 payments
  5. Alkermes, Inc. $24 2 payments
  6. Neurocrine Biosciences, Inc. $18 1 payment
  7. Takeda Pharmaceuticals U.S.A., Inc. $18 2 payments
  8. Shire North American Group Inc $15 1 payment
  9. Lundbeck LLC $14 1 payment
  10. Ironshore Pharmaceuticals Inc. $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $950 23 payments
  2. Travel and Lodging $890 2 payments
Products named General payments · program years 2019–2025
  1. Neurostar TMS Therapy System $1,484 3 payments
  2. INVEGA SUSTENNA $113 5 payments
  3. SPRAVATO $109 5 payments
  4. INVEGA TRINZA $64 3 payments
  5. ABILIFY MAINTENA $60 4 payments
  6. LATUDA $49 3 payments
  7. INVEGA $40 2 payments
  8. ARISTADA Cns $24 2 payments
  9. ARISTADA Cns $24 2 payments
  10. ARISTADA Cns $24 2 payments
  11. Other $138 11 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

1,069

Median for Psychiatry: 574

Drug cost

$13,567

Median for Psychiatry: $27,624

Branded share of claims

15.5%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Duloxetine Hcl Generic 99 $1,469
Bupropion Xl Bupropion Hcl Brand 74 $1,274
Paliperidone Er Paliperidone Brand 15 $1,115
Oxcarbazepine Generic 31 $1,047
Divalproex Sodium Er Divalproex Sodium Brand 25 $994
Trazodone Hcl Generic 83 $889
Prazosin Hcl Generic 26 $656
Lamotrigine Generic 29 $552
Clonazepam Generic 78 $548
Mirtazapine Generic 35 $528

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$17,750

Medicare's payments for the services billed

Medicare patients

51

Average age 50

Services billed

319

28 women, 23 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 57%
High blood pressure 55%
Diabetes 29%
COPD 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

25 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record